Spironolactone not reduce primary outcome, did reduce hospitalizations for heart failure

April 9, 2014, Brigham and Women's Hospital

Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitaliization to manage heart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes of Health.

The study will be published April 10, 2014 in the New England Journal of Medicine.

"There currently are no existing therapies to address the prognoses of the approximately 40 percent of patients with and a preserved ejection fraction," said Eldrin Lewis, MD, advanced heart failure specialist, Brigham and Women's Hospital (BWH) Division of Cardiovascular Medicine, Department of Medicine, study co-author. "TOPCAT is the first randomized, double-blind trial to assess the effect of a treatment—spironolactone—on clinical outcomes in this patient demographic."

"TOPCAT was robust in its design and was well-conducted, with a strong collaboration between the New England Research Institutes and clinical colleagues at Brigham and Women's Hospital and the University of Michigan, thus ensuring that the results would be reliable," said Sonja McKinlay PhD, president of New England Research Institutes, study co-senior author.

The TOPCAT trial enrolled 3,445 patients from 233 medical sites in six countries. Participants with symptomatic heart failure and a left ventricular of 45 percent or more (normal or near normal contractions) were randomized to receive either spironolactone (15 to 45 milligrams daily) or matching placebo, and were followed for an average of nearly 3.3 years.

The primary outcome consisted of death from cardiovascular causes, surviving a , or hospitalization for the management of heart failure—whichever happened first—and occurred in 320 of 1,722 patients in the spironolactone group (18.6 percent) and 351 of 1,723 patients in the placebo group (20.4 percent).

Spironolactone belongs to a class of medications known as aldosterone receptor antagonists. Spironolactone is used to treat fluid retention in patients with , liver cirrhosis or nephrotic syndrome. It is also used to treat high blood pressure, heart failure and low blood potassium (hypokalemia).

Looking at the components of the primary outcome separately, only hospitalizations, specifically for heart failure, had a significantly lower incidence for those taking spironolactone compared to placebo, with 206 patients (12.0 percent) in the spironolactone group undergoing hospitalization versus 245 patients (14.2 percent) in the placebo group.

"While the overall results failed to demonstrate a significant effect of spironolactone on the primary endpoint in TOPCAT, the study provides important insights into the potential efficacy of spironolactone in reducing the need for hospitalizations for heart failure in this population, as well as providing clues for more effectively designing future studies to reduce mortality," said Bertram Pitt, MD, University of Michigan School of Medicine, study co-senior author.

Neither total deaths nor hospitalizations for any reason were significantly reduced by spironolactone. There were no significant differences in the incidence of serious adverse events. However, spironolactone was associated with increased serum creatinine levels and a doubling of the rate of hyperkalemia (high potassium concentration in the blood), but conversely led to reduced hypokalemia (low potassium concentration in the blood). According to the researchers, such findings underscore the importance of monitoring patients prescribed spironolactone.

"When treating patients, clinicians must balance risks and benefits," said Marc A. Pfeffer, MD, PhD, BWH Division of Cardiovascular Medicine, Department of Medicine, study co-senior author. "If clinicians decide to prescribe spironolactone to their to reduce their risk of being hospitalized for heart failure, there is an associated responsibility to monitor for serum markers of kidney and electrolyte disorders which can be exacerbated by ."

Explore further: New study shows spironolactone reduces heart failure hospitalizations, but not mortality

Related Stories

New study shows spironolactone reduces heart failure hospitalizations, but not mortality

November 18, 2013
A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, to be presented at the American Heart Association (AHA) Scientific Sessions, ...

Long-term use of medication does not improve symptoms for heart failure patients

February 26, 2013
Among patients with heart failure with preserved ejection fraction, long-term treatment with the medication spironolactone improved left ventricular diastolic function but did not affect maximal exercise capacity, patient ...

The mechanistic effects of spironalactone in diastolic heart failure

August 27, 2012
Mineralocorticoid receptor antagonists should be considered as a treatment option in hypertensive patients with diastolic heart failure, said Professor Burkert Pieske presenting results today of the Aldosterone Receptor Blockade ...

New data from studies bolsters case for using aldosterone antagonists in heart failure

September 19, 2011
Roughly 5 million people in the United States live with heart failure, a condition in which the heart is unable to pump blood around the body effectively. The causes and types of heart failure vary greatly, and treatment ...

Researchers find comparable long-term outcomes between diastolic and systolic heart failure patients

January 9, 2014
A new study by researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found comparable long-term outcomes between congestive heart failure patients with preserved ejection fraction commonly ...

Levosimendan improves event free survival by 50 percent in end-stage heart failure

May 27, 2013
Ambulatory levosimendan improves event free survival by 50% compared to placebo, according to results from the LevoRep Study presented today during the late breaking trial session1 of the Heart Failure Congress 2013. In a ...

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.